Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 16/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6898734 | 0.88 | NQO2 (0.61) | NQO2F2 | |
| SCHEMBL6785308 | 0.88 | F2 (0.59) | NQO2HDAC6F2NR1I2ADORA3 | |
| SCHEMBL6781239 | 0.88 | F2 (0.57) | NQO2HDAC6F2NR1I2ADORA3 | |
| SCHEMBL6782647 | 0.87 | HDAC6 (0.53) | NQO2HDAC6F2NR1I2ADORA3 | |
| SCHEMBL6778568 | 0.87 | HDAC6 (0.45) | NQO2HDAC6F2NR1I2ADORA3 | |
| SCHEMBL6779794 | 0.86 | NQO2 (0.46) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL6781845 | 0.86 | NQO2 (0.65) | NQO2F2NR1I2ADORA3SLC6A2 | |
| SCHEMBL6784845 | 0.84 | HDAC6 (0.58) | NQO2HDAC6F2NR1I2ADORA3 | |
| SCHEMBL8028179 | 0.84 | F2 (0.50) | NQO2HDAC6F2NR1I2ADORA3 | |
| SCHEMBL6775922 | 0.82 | KMT2A (0.38) | NQO2F2ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6710055-B2 | INDOLE AND BENZIMIDAZOLE ANTITHROMBOTIC COMPOUNDS, SUCH AS 1-METHYL-2-(N-AMIDINOPHENYL)-AMINOMETHYL)-5-(N-(HYDROXYCARBO QUINOLINE-8-SULFONYLAMINO)-INDOLE | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2004-03-23 | — | — | US | disclosed |
| US-20030004181-A1 | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-02 | — | — | US | disclosed |
| US-6469039-B1 | BENZIMIDAZOLES; THROMBIN- INHIBITING ACTIVITY AND THE EFFECT OF EXTENDING THROMBIN TIME | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-22 | — | — | US | disclosed |
| US-6414008-B1 | CYNAO- OR AMIDINE-SUBSTITUTED BENZIMIDAZOLES, BENOTHIAZOLES, OR BENZOXAZOLES; 2-(N-(4-AMIDINOPHENYL)AMINOMETHYL)BENZOTHIAZOLES; 2-((4-CYANOPHENYL)OXYMETHYL)IMIDAZOL(4,5-B)PYRIDINES; ANTITHROMBOTICS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6087380-A | ANTITHROMBOTIC BENZIMIDAZOLES; ANTICOAGULANTS; 2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-BENZIMIDAZOL-5-YL-CARBOXYLIC ACIDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004181-A1 | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions | F2, TFPI, FGB | NQO2 717/4885HDAC6 3755/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.